key: cord-0862349-jycxmxa3
authors: Dodds, Michael; Xiong, Yuan; Mouksassi, Samer; Kirkpatrick, Carl M.; Hui, Katrina; Doyle, Eileen; Patel, Kashyap; Cox, Eugène; Wesche, David; Brown, Fran; Rayner, Craig R.
title: Model‐informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection
date: 2021-02-23
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.14760
sha: ab349126ec9eb6c3b54692d95d67010c0be7f209
doc_id: 862349
cord_uid: jycxmxa3

During a pandemic caused by a novel pathogen (NP), drug repurposing offers the potential of a rapid treatment response via a repurposed drug (RD) while more targeted treatments are developed. Five steps of model‐informed drug repurposing (MIDR) are discussed: (i) utilize RD product label and in vitro NP data to determine initial proof of potential, (ii) optimize potential posology using clinical pharmacokinetics (PK) considering both efficacy and safety, (iii) link events in the viral life cycle to RD PK, (iv) link RD PK to clinical and virologic outcomes, and optimize clinical trial design, and (v) assess RD treatment effects from trials using model‐based meta‐analysis. Activities which fall under these five steps are categorized into three stages: what can be accomplished prior to an NP emergence (preparatory stage), during the NP pandemic (responsive stage) and once the crisis has subsided (retrospective stage). MIDR allows for extraction of a greater amount of information from emerging data and integration of disparate data into actionable insight.

Unlike endemic diseases, a pandemic triggered by a novel pathogen (NP) may be a quickly moving target defined by outbreaks of unknown duration, location and severity. Traditional drug development for new molecular entities tailored to an NP takes too long to be considered as first-line treatment. In contrast, drug repurposing is well suited to the pandemic situation because the repurposed drugs (RD) are often well characterized and usually available as marketed products. Use of approved drugs is advantageous as there is usually a lower risk of failure due to safety reasons particularly during efficacy trials, a shorter time-frame needed for drug development and less investment required. 1 Pandemic pathogens are generally either bacterial or viral, with viral pathogens greatly outnumbering their bacterial counterparts.

While the approaches are likely applicable to both, the work presented focuses on viral pandemics which are currently the principal issue.

The presented strategy for model-informed drug repurposing Figure 1 ). While the translatability of the in vitro systems to clinical outcome might be questionable, these data define the extent of actionable information. For RDs that appear promising, clinical pharmacokinetics (PK) could be explored in order to develop recommendations on optimal posology (Step 2, Figure 1 ) as there is no reason, a priori, to believe that a posology developed for a labelled indication will be optimal for treatment of an NP. In such cases, the suitability of the available safety data may need to be reassessed prior to progressing to clinical trials.

The passage of time yields data: information about NP viral kinetics becomes available. These data are used to build a viral kinetic (VK) model that links events in the viral life cycle to PK of the RD (Step 3, Figure 1 ), guiding clinical trial design.

Later in the pandemic, greater experience with RD interventions allows comparison, contrast and synthesis. As clinical response data emerge, exposure-response (E-R) analysis can be used to assess adequate exposure in the patient population and to understand factors that drive response (Steps 4, Figure 1 ). This data can loop back to the early in vitro data, and questions around dose and regimen specific to the NP can be addressed.

F I G U R E 1 MIDR strategy arranged by increasing analytical depth and knowledge generation with increasing novel pathogen understanding C avg,ss , average steady state concentrations; C max,ss , maximum steady state concentration; C min,ss , minimum steady state concentration; C t , tissue concentration; IC 50 , half maximal inhibitory concentration; HE, health economic; MBMA, model-based meta-analysis; NP, novel pathogen; PK, pharmacokinetics; RD, repurposed drug; SOA, site of action.Notes: The amount and quality of information is indicated by shade of colour (lighter shade equals least amount of information and lower quality information, darker shade equals most amount of information and higher quality information). Arrows indicate that the learnings from each step can be used to update and refine the activities of the previous steps. It is also critical that the same concentration units (e.g., μM) be calculated for all concentration values, including IC 50 values, in all steps After clinical trials are performed, large volumes of information are available, but comparisons are difficult and seeming contradictions are evident. Model-based meta-analysis (MBMA) can be employed to extract the most information from these trials to quantitatively assess drug treatment effects (Step 5, Figure 1 ).

Each of these steps is intended to facilitate action: should further time and resources be invested in a specific RD? Critically, compounds are not necessarily rejected with these tools; they are prioritized, thereby facilitating decision making whilst keeping in mind fundamental PK and PD principles including exposure at the target SOA, binding to the pharmacological target and expression of pharmacology. 2 The steps are arranged so more insightful analyses are performed as more information about the NP becomes available (Figure 1) Figure 1 by these stages.

In each step of the MIDR process, particular data are needed, and specific assumptions must be made. Below is a discussion of each of the MIDR steps described in Table 1 and Figure 1. 2.2 | Step 1. Repurposed drug product label and in vitro data RD information from the product label and publications is mined and compared to in vitro data generated for the NP, providing initial assessment of potential for use of the RD against the NP.

The suitability of the labelled posology is considered by two quantitative methods (Figure 1, Step 1) using a readily available in vitro parameter such as IC 50 : (1) comparing the ratios of in vitro IC 50 of the RD for approved marketed indication(s) relative to that of the NP and (2) reported as IC 50 . Therefore, in these initial steps IC 50 is used to provide some early indication as to whether the repurposed drug demonstrates potential activity against the target virus.

Furthermore, consider that an NP IC 50 two orders-of-magnitude higher than the IC 50 for the approved marketed indication(s) suggest a substantial increase in dose would be required to bring the RD concentration into an effective range against the NP. In order to be repurposed, the candidate must have safety coverage at the proposed posology.

The minimum ratio for initial prioritization for repurposing should be >1 for both evaluation metrics. Ratios of <1 could be acceptable if there is clear evidence from existing safety data that there is sufficient scope for a proportional increase in dose to achieve (or exceed) the desired target ratio >1 while not experiencing concentrationdependent side effects. Again, the purpose here is to rank potential

RDs, so these ratios should be thought of as down-selection and up-selection (prioritization) tools.

Activities such as generating a master list of RD label IC 50 s, f u , C avg,ss , C min,ss , C max,ss can all be performed in the preparatory stage ( 

Once initial assessment that the RD has the potential to reach effective concentrations has been achieved, the potential for the RD to be optimized can be further evaluated. Investigations at this stage include determining (or predicting) NP exposure at the SOA, considering the predicted RD concentration within its therapeutic window (including safety margins), adjustments of posology to account for the acute nature of the NP, and making assumptions about the interaction between NP and RD at the SOA.

This step ( Figure 1, Step 2) considers the potential for differences in the SOA between the indication with marketing approval and the NP. Free drug concentration can be a useful surrogate for tissue concentration. If available, PK studies that directly measure RD concentration in target tissues are ideal. If not, mathematical modelling such as physiologically-based pharmacokinetic models (PBPK) may be utilized to account for altered partitioning, transporter utilization and tissue metabolism. 2, 3 Through experience during the current pandemic, we recommend that the ratio of free drug tissue (SOA) concentration vs. IC 50 is the key metric for consideration and should ideally be greater than 1. Repurposed drugs that achieve or exceed this target can undergo posology optimization for use against the NP. During posology optimization, differences in methodology utilized for the in vitro IC 50 measurement must be taken into account 3, 4 (see Case Example 2 in the Supplementary Materials). For example, in vitro tests of repurposed anti-viral compounds are often performed in cell culture assays with low (<20%) or no protein in the assay. Human plasma has significant circulating proteins, so free RD concentration in situ may be vastly different from that observed in an in vitro assay (as was seen in SARS-CoV-2 with ivermectin). 5, 6 Additionally, cell culture systems may not mimic normal cell function to an extent that allows determination of the true tissue concentration ratio, so the in vivo IC 50 may differ from that observed in vitro. 7 Dose-response and/or E-R can be highly informative and, in an adequate and well-controlled clinical trial, can be considered pivotal.

In the review process, the question of "do we have the right dose regimen" is of paramount importance, especially for drugs whose safety profile could impact decisions about risk-benefit.

Several layers of decisions are informed by MIDR. Dose/E-R modelling supports timing of dose start, dose selection and duration of therapy and the validation of endpoint selection. While these inform the optimal treatment for an individual, they also provide information on the percentage of the population that will require prophylaxis or treatment to reduce NP shedding in the community. Applying This variability in patient demographics and study conduct will further increase as the pandemic spreads. Moreover, the standard-of-care (SoC) will be geographically diverse and will evolve over time. The NP itself may also change (mutations, changes in virulence factors, differential effects by geography).

This creates a huge potential to obtain insights into the impact of drug treatment on the course of disease, vital signs and biomarkers. Model-based approaches can also utilize data from early stages of a pandemic to explore potential outcomes and the associated uncertainty. Weighting schemes can also be employed to address the variability in data quality, as seen in MBMA where studies are commonly weighted based on sample size. This could be expanded to in vitro or preclinical studies, where potency information from multiple data sources is weighted with consideration to data quality and validity, particularly as the quality of data improves throughout the duration of a pandemic. Importantly, as data quality improves and in silico models are refined, analyses which pool data from early and late stages of the pandemic could address these changes in a quantitative manner, and further guide decision making.

Drug repurposing has the potential to identify effective treatments in an emerging pandemic while more specific treatments and preventions are developed. A five-step process of MIDR to screen and prioritize compounds for use as a first response to an NP is suggested.

Organized around the increasing level of information about the pandemic's pathogen, these steps are as follows. strategy proposed in this manuscript, will allow not only the retrospective evaluation of drug effects for drug repurposing, but will also allow tools and strategies to be developed in preparation for future pandemic events.

These steps can also be organized around implementation relative to the NP's emergence. Benjamin Franklin offered the advice that "an ounce of prevention is worth a pound of cure". 23 This axiom is assumed to relate to health, but in fact it was put forward as advocacy for fire awareness and prevention. More broadly, his advice relates to disaster preparedness and advocates, as do these authors, performing as much work as feasible ahead of the disaster. In the preparatory stage, infrastructure and tools are developed.

As outlined in Table 1 Steps in the responsive stage must be carried out rapidly after an NP is identified, as the utility of any repurposed drug must be assessed in the context of its ability to inhibit a specific event caused by the NP. These steps leverage work done in the preparatory stage to reduce time for data acquisition and afford the ability to rank candidates for repurposing. Aspects of Steps 1-5 occur in the responsive stage; the key is to front-load as much as possible into the preparatory stage to identify promising RD as quickly as possible.

In the retrospective stage, reflection suggests updates to preparatory activities seeking continuous improvement. This includes reviewing translatability of results (e.g., suitability of cell lines), updating models (popPK, E-R, VK), refining clinical outcome choices and streamlining study design (e.g., platform trial design).

Model-informed drug repurposing has the ability to streamline treatment-to-patient decisions and logistics in response to a pandemic. By breaking the process into steps, the available information at any given stage is used to prioritize plausible treatments into clinic.

Decision making and prioritization can be improved by integrating RD PK and in vitro data, NP VK, clinical endpoints and learnings from MBMA. This model-informed drug repurposing strategy provides a framework for an actionable, pharmacometric approach to novel pandemic preparedness, response and retrospection.

This work has been supported and funded by the Bill and Melinda

Gates Foundation.

Drug repurposing: progress, challenges and recommendations

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments

The pharmacokinetic and pharmacodynamic properties of hydroxychloroquine and dose selection for COVID-19: putting the cart before the horse

Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19

Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning

Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics

Strategies for containing an emerging influenza pandemic in Southeast Asia

Kinetics of influenza A virus infection in humans

Viral load drives disease in humans experimentally infected with respiratory syncytial virus

Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Duration of viral shedding of discharged patients with severe COVID-19

Model-informed drug repurposing: viral kinetic modeling to prioritize rational drug combinations for COVID-19

Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: an example in SARS-CoV-2

Viral kinetic modeling: state of the art

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial

Activity of oral ALS-008176 in a respiratory syncytial virus challenge study

Endpoints for randomized controlled clinical trials for COVID-19 treatments

Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics

Clinical trials in the pandemic age: What is fit for purpose?

Comet Initiative. Core outcome set developer's response to COVID-19. Secondary core outcome set developer's response to COVID-19 2020

Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond

Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer

Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: assessing the impact

Multivariate network meta-analysis of survival function parameters

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations

Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection